Confluence Life Sciences
acquired by Aclaris TherapeuticsSaint Louis, US · Delaware corporation · 1 known investors
Technology-focused company on rational drug design for cancer and chronic inflammatory diseases (acquired by Aclaris Therapeutics in August 2017).
Founders & leadership
JB
Jennifer BohnertExecutive
WS
Walter SmithExecutive
JM
Joseph MonahanNamed on SEC filing
Board
DJ
Daniel JaniakBoard director
CB
Charles BoltenBoard director
TS
Thomas SmartBoard director
KS
Investors · 1
Reported raises · per SEC filings
Form D private placements$4.8M disclosed across 1 round · 2016
▶$4.8MraisedApr 2016 · 16 investors · Other Health CareRule 506(b)
▶$4.8MraisedApr 2016 · 16 investors · Other Health Care
Rule 506(b)Officers, directors & promoters on the filing
- Daniel JaniakDirector
- Jennifer BohnertExecutive Officer
- Walter SmithExecutive Officer, Director
- Joseph MonahanExecutive Officer, Director
- Charles BoltenDirector
- Thomas SmartDirector
- Kyparissia SirinakisDirector
- Offering amount
- $5.4M
- Amount sold
- $4.8M
- Minimum investment
- $1
- First sale
- Apr 2016
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
In the news
Frequently asked questions
- What does Confluence Life Sciences do?
- Technology-focused company on rational drug design for cancer and chronic inflammatory diseases (acquired by Aclaris Therapeutics in August 2017).
- Who are Confluence Life Sciences's investors?
- Confluence Life Sciences's investors include Epidarex Capital.
- How much funding has Confluence Life Sciences raised?
- Confluence Life Sciences has disclosed $4.8M raised across 1 round.
- Who acquired Confluence Life Sciences?
- Confluence Life Sciences was acquired by Aclaris Therapeutics.
- Where is Confluence Life Sciences headquartered?
- Confluence Life Sciences is headquartered in Saint Louis, US.